Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Dermatology

Date Submitted: Jun 30, 2023
Open Peer Review Period: Jun 30, 2023 - Aug 25, 2023
Date Accepted: Feb 27, 2024
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

From the Cochrane Library: Leukotriene Receptor Antagonists for Eczema

Dellavalle RP, Toledo LM, Sivesind TE, Rodriguez R

From the Cochrane Library: Leukotriene Receptor Antagonists for Eczema

JMIR Dermatol 2024;7:e50434

DOI: 10.2196/50434

PMID: 38607671

PMCID: 11053388

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

From the Cochrane Library: Leukotriene Receptor Antagonists for Eczema

  • Robert P. Dellavalle; 
  • Lauren Marie Toledo; 
  • Torunn E. Sivesind; 
  • Ramiro Rodriguez

ABSTRACT

Background:

N/A

Objective:

N/A

Methods:

N/A

Results:

N/A

Conclusions:

N/A


 Citation

Please cite as:

Dellavalle RP, Toledo LM, Sivesind TE, Rodriguez R

From the Cochrane Library: Leukotriene Receptor Antagonists for Eczema

JMIR Dermatol 2024;7:e50434

DOI: 10.2196/50434

PMID: 38607671

PMCID: 11053388

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.